TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34302350

Group type: EXPERIMENTAL
Intervention: Prenatal cholecalciferol (vitamin D-3) dose of 0, 4200, 16,800, or 28,000 IU/wk from 17 to 24 wk of gestation followed by placebo to 6 mo postpartum
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: 28,000 IU cholecalciferol/wk both prenatally and postpartum
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Various biological, sociodemographic, and laboratory-related characteristics including feeding practices
Number of subjects: 1300
Study: 32657608

Group type: EXPERIMENTAL
Intervention: Objective Response (OR)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Non-Objective Response (non-OR)
Number of subjects: 596
Study: 36107466

Group type: EXPERIMENTAL
Intervention: High-dose sucroferric oxyhydroxide (2000 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Washout (control)
Number of subjects: 28
Study: 33648870

Group type: EXPERIMENTAL
Intervention: Renal-specific oral nutritional supplement (RS-ONS) during hemodialysis sessions, given in two portions: 100 mL after 1 hour and 137 mL 45 minutes before the end of hemodialysis.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Renal-specific oral nutritional supplement (RS-ONS) at home.
Number of subjects: 36
Study: 32960094

Group type: EXPERIMENTAL
Intervention: Ethanol 86% v/v gel
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ethanol 89.5% v/v solution
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ethanol 72.4% v/v solution
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference solution (70% v/v ethanol)
Number of subjects: 18
Study: 35713119

Group type: EXPERIMENTAL
Intervention: Focused ESWT
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Radial ESWT
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sham ESWT
Number of subjects: 99
Study: 33380179

Group type: EXPERIMENTAL
Intervention: Cemented fixation
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Uncemented fixation
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Hybrid fixation
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 105
Study: 32912948

Group type: EXPERIMENTAL
Intervention: Enhanced, personalised smoking cessation support package including CT scan images
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Standard best practice smoking cessation support
Number of subjects: 1040
Study: 35123362

Group type: EXPERIMENTAL
Intervention: Contingency management (CM) delivered via telehealth for 4 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Monitoring control
Number of subjects: 27
Study: 34347132

Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g per day for 40 days)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Control group (without vitamin C)
Number of subjects: 329
Study: 35799672

Group type: EXPERIMENTAL
Intervention: Oral sorafenib combined with transcatheter arterial chemoembolization (TACE)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE) only
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: DWI
Number of subjects: 88

Group type: COMPARATOR
Intervention: MR plain scan
Number of subjects: 88
Study: 32428656

Group type: EXPERIMENTAL
Intervention: Herbal medicine use
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Self-medication with herbal medicines
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Medicinal plant species reported
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Factors associated with herbal medicine use
Number of subjects: 634
Study: 35856224

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg, once a day, orally)
Number of subjects: 112
Study: 33626105

Group type: EXPERIMENTAL
Intervention: qSOFA score 1
Number of subjects: 11621

Group type: EXPERIMENTAL
Intervention: qSOFA score 2
Number of subjects: 11621

Group type: EXPERIMENTAL
Intervention: qSOFA score 3
Number of subjects: 11621

Group type: EXPERIMENTAL
Intervention: qSOFA score
Number of subjects: 11621
Study: 33024552

Group type: EXPERIMENTAL
Intervention: Green tea (three cups/day after meals) + usual treatment (deferasirox iron chelator and on demand blood transfusion)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (only usual treatment)
Number of subjects: 68
Study: 33686922

Group type: EXPERIMENTAL
Intervention: Stress‐intervention condition
Number of subjects: 177

Group type: COMPARATOR
Intervention: Stress‐placebo condition
Number of subjects: 177

Group type: COMPARATOR
Intervention: No‐stress‐placebo control condition
Number of subjects: 177
Study: 32123197

Group type: EXPERIMENTAL
Intervention: Nx4 (three tablets)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 35201674

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg (EM)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg (CM)
Number of subjects: 668

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg (overall population)
Number of subjects: 668

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 668
Study: 33121984

Group type: EXPERIMENTAL
Intervention: 0.75 % HP-containing toothpaste (Toothwhole white)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 0.75 % HP-containing toothpaste (Vussen 7)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 2.8 % HP-containing toothpaste (Vussen 28)
Number of subjects: 49

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 49
Study: 35473653

Group type: EXPERIMENTAL
Intervention: Interactive Internet-based cognitive-behavioral program (n=148)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Static Internet-based cognitive-behavioral program (n=145)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Both interventions (interactive and static)
Number of subjects: 293
Study: 34544470

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 160 mg once daily
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 32660517

Group type: EXPERIMENTAL
Intervention: 750 mg amoxicillin three times daily for 3 months
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 35514992

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated vaccination (TIV)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 32876469

Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (LRM)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (LRM) and PEEP
Number of subjects: 21
Study: 35839450

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Desmopressin followed by exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Exercise followed by desmopressin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 32
Study: 32798112

Group type: EXPERIMENTAL
Intervention: 3D printing group
Number of subjects: 81

Group type: COMPARATOR
Intervention: conventional group
Number of subjects: 81
Study: 33309467

Group type: EXPERIMENTAL
Intervention: Affective and Sensory Psychotherapy Module (ASPM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 32600481

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Mitochondrial-enhancing agents (CT)
Number of subjects: 163
Study: 35718069

Group type: EXPERIMENTAL
Intervention: Disposable distal caps (group B)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Fixed distal caps (group A)
Number of subjects: 400
Study: 616389365

Group type: EXPERIMENTAL
Intervention: Dermabrasion (Group A)
Number of subjects: 90
Study: 35377043

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training once a week for 6 weeks
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 200
Study: 33720478

Group type: EXPERIMENTAL
Intervention: No further axillary treatment recommended for underrepresented groups (premenopausal, HER2+/triple‐negative tumors, invasive lobular carcinoma)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Multi-disciplinary discussion recommended for mastectomy patients
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Need for more data to change practice
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Accrual challenges to a clinical trial
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Recommendations for patients treated with NAC
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Axillary radiation recommendation by radiation oncologists
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: No further axillary treatment recommendation by surgeons
Number of subjects: 94
Study: 35653615

Group type: EXPERIMENTAL
Intervention: IV golimumab 2 mg/kg at weeks 0 and 4, then every 8 weeks through week 52
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo at weeks 0, 4, and 12, crossover to IV golimumab at week 16
Number of subjects: 112
Study: 34736721

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 575

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 575
Study: 33683919

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 834

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 834
Study: 33052969

Group type: EXPERIMENTAL
Intervention: AR DSpecs (Augmented Reality Digital spectacles)
Number of subjects: 21
Study: 35582897

Group type: EXPERIMENTAL
Intervention: Dextrose gel followed by breastfeeding
Number of subjects: 629

Group type: COMPARATOR
Intervention: Control group (CG) received only breastfeeding
Number of subjects: 629
Study: 33043381

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide plus resistance band training
Number of subjects: 68

Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 68
Study: 33176272

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 126

Group type: COMPARATOR
Intervention: Cupping therapy
Number of subjects: 126
Study: 35640544

Group type: EXPERIMENTAL
Intervention: Normothermic polarizing cardioplegia (n=8)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Depolarizing cardioplegia (n=5)
Number of subjects: 13
Study: 33371083

Group type: EXPERIMENTAL
Intervention: Isokinetic training (IKT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Core stabilization training (CST)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 36214139

Group type: EXPERIMENTAL
Intervention: Group 1 (ACD 2.80 to 2.99 mm)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Group 2 (ACD ≥ 3.00 mm)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 298
Study: 33452923

Group type: EXPERIMENTAL
Intervention: 12‐mg dexamethasone (2 × 12‐mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 6‐mg dexamethasone (4 × 6‐mg)
Number of subjects: 60
Study: 32476469

Group type: EXPERIMENTAL
Intervention: Nature condition
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Built condition
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 18
Study: 35074820

Group type: EXPERIMENTAL
Intervention: Guided web-based behavioural activation intervention (InterAKTIV)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 128
Study: 33867499

Group type: EXPERIMENTAL
Intervention: Exercise plus supplementation (Ex + Suppl; n = 34)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care (control; n = 36)
Number of subjects: 70
Study: 35172441

Group type: EXPERIMENTAL
Intervention: Preoperative neuromuscular electrical stimulation (NMES) for 20 minutes, 5 times a day, for 6 weeks before surgery.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with no preoperative intervention, placed on a 6-week waiting list for surgery.
Number of subjects: 40
Study: 33136047

Group type: EXPERIMENTAL
Intervention: 50 Gy radiation dose (1 fractioned dose of 2 Gy per day, 5 days per week, for 5 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 70 Gy radiation dose (1 fractioned dose of 2 Gy per day, 5 days per week, for 7 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 50 Gy radiation dose
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 70 Gy radiation dose
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no radiation)
Number of subjects: 36
Study: 35182242

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFT)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (CCT)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Combined NFT/CCT training
Number of subjects: 121

Group type: COMPARATOR
Intervention: All training groups (NFT, CCT, NFT/CCT)
Number of subjects: 121
Study: 34587236

Group type: EXPERIMENTAL
Intervention: Vasopressin and methylprednisolone (n = 245)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Placebo (n = 267)
Number of subjects: 512
Study: 32565482

Group type: EXPERIMENTAL
Intervention: Seated arm ergometry training at moderate intensity (65%-75% HRpeak), three times per week for 12 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care alone (control group).
Number of subjects: 0
Study: 36069629

Group type: EXPERIMENTAL
Intervention: ACDHF with short‐segment plate and self‐locking stand‐alone cages (hybrid group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ACDF with long‐segment plate (control group)
Number of subjects: 60
Study: 34682785

Group type: EXPERIMENTAL
Intervention: Suction (S) with 20 actuations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-suction (NS) with 15 actuations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suction (S) with 15 actuations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capillary sampling with stylet slow-pull (CSSS) with 15 actuations
Number of subjects: 0
Study: 35293068

Group type: EXPERIMENTAL
Intervention: Oleoylethanolamide (OEA) 125 mg per day for 2 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 33303427

Group type: EXPERIMENTAL
Intervention: Counselling intervention (weave) delivered by trained family doctors; uptake rate: 49%.
Number of subjects: 272

Group type: COMPARATOR
Intervention: Usual care provided by control doctors with standard IPV information.
Number of subjects: 272
Study: 35094742

Group type: EXPERIMENTAL
Intervention: Psychosocial assessment after self-harm
Number of subjects: 0

Group type: COMPARATOR
Intervention: No assessment
Number of subjects: 0
Study: 34516957

Group type: EXPERIMENTAL
Intervention: 30 min of moderate aerobic exercise on a cycle ergometer
Number of subjects: 99

Group type: COMPARATOR
Intervention: 30 min of simple lower body stretching routine (active control treatment)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Watching a popular sitcom (passive control treatment)
Number of subjects: 99
Study: 35471470

Group type: EXPERIMENTAL
Intervention: SOR007 0.15%
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: SOR007 1.0%
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: SOR007 2.0%
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 23
Study: 33800415

Group type: EXPERIMENTAL
Intervention: Active MBS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 10
Study: 35582123

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 33122899

Group type: EXPERIMENTAL
Intervention: Hypnosis (15-minute session)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham (15-minute session)
Number of subjects: 21
Study: 34983040

Group type: EXPERIMENTAL
Intervention: Local anaesthetic to attenuate somatosensory inputs to the big toes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham anaesthetic (control group)
Number of subjects: 0
Study: 33346477

Group type: EXPERIMENTAL
Intervention: Metformin at a dose of 1700 mg/day for 12 months
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Metformin at a dose of 1700 mg/day for 12 months, correction of vitamin D deficiency with cholecalciferol at a dose of 4000 IU/day for 6 months, then 2000 IU/day for another 6 months, and melatonin preparation at a dose of 3 mg/day for 6 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 54
Study: 33058901

Group type: EXPERIMENTAL
Intervention: Face-to-face inclusion
Number of subjects: 84

Group type: COMPARATOR
Intervention: Face-to-face exclusion
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Avatar inclusion
Number of subjects: 84

Group type: COMPARATOR
Intervention: Avatar exclusion
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Computer VR-agent inclusion
Number of subjects: 84

Group type: COMPARATOR
Intervention: Computer VR-agent exclusion
Number of subjects: 84
Study: 32461510

Group type: EXPERIMENTAL
Intervention: Sensodyne toothpaste
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Crest toothpaste
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Colgate toothpaste
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dental desensitizer
Number of subjects: 50
Study: 36241996

Group type: EXPERIMENTAL
Intervention: CBT + E-TRAIN
Number of subjects: 138

Group type: COMPARATOR
Intervention: CBT
Number of subjects: 138
Study: 32507638

Group type: EXPERIMENTAL
Intervention: Preoperative physiotherapy education (POPE) combined with postoperative physiotherapy (POP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Postoperative physiotherapy (POP) only
Number of subjects: 21
Study: 32754966

Group type: EXPERIMENTAL
Intervention: HPV vaccination (offered to women born in 1993)
Number of subjects: 35799

Group type: COMPARATOR
Intervention: No HPV vaccination (women born in 1983)
Number of subjects: 35799
Study: 35338628

Group type: EXPERIMENTAL
Intervention: Health education intervention focusing on preventing childhood unintentional injuries.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 33309237

Group type: EXPERIMENTAL
Intervention: Behavioral Economic Adherence for Teens (BEAT) intervention, which includes a text messaging system and a graphical user interface
Number of subjects: 12
Study: 35730719

Group type: EXPERIMENTAL
Intervention: Prophylactic escitalopram oxalate (n = 60)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo (n = 65)
Number of subjects: 125
Study: 33999179

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 4769

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 4769
Study: 32644110

Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA (ctDNA) positive
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: ctDNA positive and CTC positive
Number of subjects: 196
Study: 35039194

Group type: EXPERIMENTAL
Intervention: V114 lot 1
Number of subjects: 2340

Group type: EXPERIMENTAL
Intervention: V114 lot 2
Number of subjects: 2340

Group type: EXPERIMENTAL
Intervention: V114 lot 3
Number of subjects: 2340

Group type: COMPARATOR
Intervention: V114 combined lots
Number of subjects: 2340

Group type: COMPARATOR
Intervention: V114
Number of subjects: 2340
Study: 34465201

Group type: EXPERIMENTAL
Intervention: 20 mg oral fluoxetine once daily for 6 months
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Matching placebo for 6 months
Number of subjects: 1500
Study: 35262918

Group type: EXPERIMENTAL
Intervention: Unilateral upper limb training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bilateral upper limb training
Number of subjects: 32
Study: 32651467

Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1) administered every two weeks for four cycles (two cycles prior to first HDR, two cycles prior to second HDR) combined with androgen deprivation therapy (ADT) and high-dose-rate (HDR) brachytherapy.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1)
Number of subjects: 6
Study: 35476592

Group type: EXPERIMENTAL
Intervention: Comprehensive Approach to Reintegrate clients with multiple problems (CARm)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 207
Study: 32911988

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (600 IU/day plus 50,000 IU/week)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Low-dose vitamin D (600 IU/day plus placebo weekly)
Number of subjects: 59
Study: 32303164

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 0
Study: 36121247

Group type: EXPERIMENTAL
Intervention: PASCAL system
Number of subjects: 180

Group type: COMPARATOR
Intervention: MitraClip system
Number of subjects: 180
Study: 34513765

Group type: EXPERIMENTAL
Intervention: Active tDCS and cognitive training (20 min/session, total 20 sessions, for 12 weeks)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham tDCS and cognitive training
Number of subjects: 13
Study: 32621898

Group type: EXPERIMENTAL
Intervention: 1-piece intraocular lens (IOL)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: 3-piece intraocular lens (IOL)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Capsule tension ring (in PEX group)
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: No capsule tension ring (in PEX group)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Control group (no PEX)
Number of subjects: 1400
Study: 35530957

Group type: EXPERIMENTAL
Intervention: Radical laparo-gastroscopic esophagectomy (LGE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radical laparo-thoracoscopic esophagectomy (LTE)
Number of subjects: 0
Study: 32681922

Group type: EXPERIMENTAL
Intervention: Donor stool (FMT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (autologous stool)
Number of subjects: 62
Study: 35879537

Group type: EXPERIMENTAL
Intervention: OFRA intervention (mobility and falls prevention classes, examination of bone health, consultation on safety in the home)
Number of subjects: 9408

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 9408